

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

NCT05270733

Status	RECRUITING
Phase	Phase 4
Sponsor	University Hospitals Cleveland Medical Center
Enrollment	56 participants

Key Eligibility Criteria

Inclusion (8)

- Diagnosed with plaque-type psoriasis defined by either:
- A board-certified dermatologist, OR
- Dermatology Nurse Practitioner, OR
- Skin punch biopsy
- Insurance that includes an anti-p40 biologic (ustekinumab/Stelara) and at least one anti-p19 biologic (guselkumab/Tremfya or risankizumab/Skyrizi)
- ... and 3 more (see full listing online)

Exclusion (7)

- Pregnant, breastfeeding, or planning to get pregnant 8 weeks before, during, and 8 weeks after the study.
- Inability to provide informed consent
- Inability to secure ustekinumab and either gusekumab or risankizumab for use while on trial
- Use of tanning booths for at least 4 weeks prior to baseline visit
- Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit and for duration of trial
- ... and 2 more (see full listing online)

Locations (1 total)

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States